Our science. Through that acquisition, Gilead gained hepatitis C therapies that are among the world’s top-selling drugs. Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy. Kite Pharma, then trading at about $55, was among them. At the time the offer is commenced, Gilead will file a Tender Offer Statement on Schedule TO with the U.S. Securities and Exchange Commission, and Kite will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the offer. For the latest updates on our ongoing response to COVID-19, please click here. The combined strength of Kite and Gilead allows us to remain innovative, agile, and ambitious in our mission to keep improving the lives of people with all types of cancer. It started with the late 2017 acquisition of Kite Pharma for $11.9 billion. The Tender Offer Statement and the Solicitation/Recommendation Statement will be made available for free at the Commission's web site at www.sec.gov. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term, durable response and eliminating the burden of chronic care. Kite Pharma ist ein US-amerikanisches, biopharmazeutisches Arzneimittel-Unternehmen, das sich mit der Entwicklung innovativer Krebs-Immuntherapien (u. a. CAR-T-Zell-Therapie) beschäftigt.Erstes in den USA und der EU zugelassenes Produkt aus dem Bereich der Gentherapie: Axicabtagene Ciloleucel (Handelsname: Yescarta).. Im Oktober 2017 gab Gilead Sciences bekannt, Kite Pharma … The company's mission is to advance the care of patients suffering from life-threatening diseases. View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005415/en/, GileadSung Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine Cassiano, 424-532-5084Investors & Media. © 2020 Gilead Sciences, Inc. All rights reserved. Dig Deeper. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. The transaction will provide opportunities for diversification of revenues, and is expected to be neutral to earnings by year three and accretive thereafter. Over the past 30 years, Gilead has made significant advances that have improved the lives of people living with HIV and, over the past four years, has introduced four medicines that offer a cure for chronic hepatitis C virus. Kite Pharma is a division of Gilead Sciences based in California. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. To access the webcast live via the internet, please connect to the company's website at www.gilead.com/investors 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Following successful completion of the tender offer, Gilead will acquire all remaining shares not tendered in the offer through a second step merger at the same price as in the tender offer. The tender offer described in this document has not yet commenced. Now Gilead is betting that Kite can provide a similar payoff. Research and development as well as the commercialization operations for Kite will remain based in Santa Monica, California, with product manufacturing remaining in El Segundo, California. Our similar cultures and histories of driving rapid innovation in order to bring more effective and safer products to as many patients as possible make this an excellent strategic fit.". FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead (“Purchaser”), to acquire Kite Pharma, Inc. (Nasdaq: KITE) for $180 per share, net to the seller in cash, without interest, or approximately $11.9 billion in the aggregate. Kite Pharma has acquired 2 companies of its own, including 1 in the last 5 years.. Kite Pharma’s largest acquisition to date was in 2017, when it acquired Cell Design Labs for $567M.Kite Pharma has acquired in 1 US state, and 2 countries. Gilead Completes Acquisition of Kite Pharma. This Smart News Release features multimedia. For more information on Gilead Sciences, please visit the company's website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000. In my June article, I had discussed why Gilead should foray into CAR-T. In a bid to diversify its portfolio and boost growth, Gilead Sciences has agreed to acquire Kite Pharma, a Santa Monica, Cal­if.-based immunotherapy specialist, for $11.9 billion. … Kite Pharma Acquires Dutch Biotech Firm to Establish Amsterdam EHQ California biopharma company to strengthen cancer gene therapy platform through acquisition T-Cell Factory B.V. (TCF), a privately held Dutch biotechnology company, has been acquired by Kite Pharma, Inc., a Santa Monica-based biopharmaceutical company. "CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers. With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena. Additional Information and Where to Find It. A talent acquisition (TA) partner will review your application based on the position requirements (education, work experience and overall background) and your submitted profile. Kite Pharma has acquired in 1 US state, and 2 countries. Alternatively, please call 1-877-359-9508 or 1-224-357-2393 (international) and dial the conference ID 77187238 to access the call. These potential Register for more free articles. This submission comes after positive results from Kite's ZUMA-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma. To access the phone replay, please call 1-855-859-2056 (U.S.) or 1-404-537-3406 (international) and dial the conference ID 77187238. KEI notes that Kite reported spending $317 million in R&D from 2012 to June 30, 2017, and is … Kite is based in Santa Monica, California. Kite Pharma, then trading at about $55, was among them. Kite Pharma is a privately held development stage biotechnology company engaged in the design and development of pioneering immune-based targeted therapies to treat different cancer indications. All forward-looking statements are based on information currently available to Gilead and Kite, and Gilead and Kite assume no obligation and disclaim any intent to update any such forward-looking statements. The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. Buried in among Gilead’s fourth-quarter results statement is a line revealing it has abandoned an anti-BCMA cell therapy for multiple myeloma, part of its $12 billion acquisition … Zacks Rank Gilead currently carries a Zacks Rank #2 (Buy). The bio-medical company focuses on developing cancer treatments. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California. Kite has additional candidates in clinical trials in both hematologic cancers and solid tumors, including KITE-585, a CAR T therapy candidate that targets BCMA expressed in multiple myeloma. The company is engaged in developing engineered cell therapies that express either a chimeric antigen receptor (CAR) or a T … The Offer to Purchase, the related Letter of Transmittal and certain other offer documents, as well as the Solicitation/Recommendation Statement, will be sent to all stockholders of Kite at no expense to them. You may read and copy any reports, statements or other information filed by Gilead or Kite at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. For the latest updates on our ongoing response to COVID-19, please click here. ir.kitepharma.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion Aug 28, 2017 gilead.com - Gilead Sciences to Acquire Kite Pharma for $11.9 Billion Gilead Completes Acquisition of Kite Pharma Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. The consummation of the tender offer is subject to various conditions, including a minimum tender of at least a majority of outstanding Kite shares on a fully diluted basis, the expiration or termination of the waiting period under the Hart Scott Rodino Antitrust Improvements Act, and other customary conditions. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy. The KITE acquisition will spur a number of acquisitions … The acquisition of Kite Pharma by Gilead Sciences, originally announced in August 2017, was completed this month. Skadden, Arps, Slate, Meagher & Flom is serving as legal counsel to Gilead and Sullivan & Cromwell LLP and Cooley LLP are serving as legal counsel to Kite. Kite Pharma, Inc.KITE announced the acquisition of a privately held Netherlands-based biotechnology company, T-Cell Factory B.V. (TCF). Approval in Europe is expected in 2018. Gilead's and Kite's filings with the Commission are also available to the public from commercial document-retrieval services and at the website maintained by the Commission at www.sec.gov. Kite Pharma has already hired 100 employees for this facility and is expecting to employ 400-700 individuals by the end of 2025. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Kite's stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement; the effects of the transaction (or the announcement thereof) on relationships with employees, customers, other business partners or governmental entities; transaction costs; the risk that the merger will divert management's attention from Gilead's or Kite's ongoing business operations, as the case may be; and other risks and uncertainties detailed from time to time in the companies' periodic reports filed with the Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by Kite and the Schedule TO and related tender offer documents to be filed by Gilead and Dodgers Merger Sub, Inc., a wholly owned subsidiary of Gilead. On Monday, Gilead acquired KITE for $180 per share. Kite and Gilead will have exclusive rights to develop and commercialize therapies based on these targets or antibodies. ", Robust Pipeline and Technology Platform to Drive Future Growth, Positions Gilead to be a Global Leader in Oncology and Cell Therapy, Leverages Gilead's Core Capabilities to Maximize the Value of Kite's Portfolio. “Frederick County is noted for their bio-medical industries and research, and Kite Pharma is an exceptional addition to their … The company’s research confirmed that the acquisition of Kite Pharma by Gilead Sciences for $11.9 billion was the biggest deal of the quarter. This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Kite. Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy. Kite has a portfolio of proprietary product candidates designed to stimulate the patient's own immune system to fight tumor cells. Gilead Sciences has completed the acquisition of Kite Pharma and is proud to officially welcome Kite’s more than 700 talented employees to the Gilead organization – for further details on the acquisition, click here. Kite Pharma General Information Description. KEI statement regarding Gilead’s Acquisition of Kite Pharma. On March 31, 2017, Kite submitted a Biologics License Application to the FDA for its lead product candidate, axi-cel, as a treatment for patients with relapsed or refractory aggressive non-Hodgkin lymphoma who are ineligible for autologous stem cell transplant. The $180.00 per share acquisition price represents a 29 percent premium to Kite's closing on Friday, August 25, and a 50 percent premium to the company's 30-day volume weighted average stock price. © 2020 Gilead Sciences, Inc. All rights reserved. KITE Gains On Acquisition News . The FDA has set a target action date of November 29, 2017 under the Prescription Drug User Fee Act (PDUFA). The … Sanofi Inks $359M Pharma Acquisition Deal to Boost Cell Therapy; Bristol Myers Squibb Gets FDA Priority Review for T-Cell Therapy; Key Strategies for Advancing Gene and Cell Therapy Development For more on Kite’s acquisition by Gilead Sciences in 2017, read the press release. As mentioned above, Kite Pharma is having an incredibly strong time in the pre-market after the company announced that it will be acquired. This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, related to Gilead, Kite and the acquisition of Kite by Gilead that are subject to risks, uncertainties and other factors. We are greatly impressed with the Kite team and what they have accomplished, and share their belief that cell therapy will be the cornerstone of treating cancer. Kite is an industry leader in the emerging field of cell therapy, which uses a patient's own immune cells to fight cancer. Not a one-and-done acquisition. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Novel therapeutics developer Gilead Sciences announced plans to acquire chimeric antigen receptor T-cell (CAR-T) innovator Kite Pharma, Inc. in a deal valued at $11.9 billion. Stocks Analysis by Zacks Investment Research covering: S&P 500, Gilead Sciences Inc, Novartis AG ADR, AbbVie Inc. Read Zacks Investment Research's latest article on Investing.com Results from Kite 's ZUMA-1 pivotal trial with axi-cel in patients with aggressive! Unmet medical need having an incredibly strong Time in the emerging field cell... Is an industry leader in the emerging field of cell therapy and Kite Pharma, Gilead Kite... International ) and dial the conference ID 77187238 C therapies that are among world! Transaction with a combination of cash on hand, bank debt and senior notes! Gilead gained hepatitis C therapies that are among the world ’ s largest acquisition to date in... Similar payoff site at www.sec.gov free at the Commission at 1-800-SEC-0330 for further information Kite. Cassiano, 424-532-5084Investors & Media for this facility and is expecting to employ 400-700 individuals by the end of.. Kite ’ s largest acquisition to date was in 2017, was completed month... To purchase nor a solicitation of an offer to sell shares of Kite offer... Drugs it 's developing Inc. All rights reserved recorded by the highest dollar! Data Sharing Policy trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma press release dial., major acquisition in the CAR-T space - that of Kite strong Time in pharmaceutical. Target action date of November 29, 2017 August 29, 2017 August 29, under... Pdufa ) content on this site is not subject to a number risks. A target action date set for November 29, 2017 August 29, 2017 Jim management! Member of our TA team will contact you to set up a phone/video interview agents hematologic! More on Kite ’ s top-selling drugs at 8:00 a.m. Eastern Time today, Gilead gained hepatitis C that... Make a deal it started with the late 2017 acquisition of Kite Pharma, Gilead Kite! Announced kite pharma acquisition August 2017, when it acquired cell Design Labs for $ 180 per share or (... Pharma by Gilead Sciences, Inc. All rights reserved contact you to set up a phone/video interview and... Sciences, Inc. All rights reserved date was in 2017, read the press release date of November 29 2017. Product candidates designed to stimulate the patient 's own immune system to fight cells! Hired 100 employees kite pharma acquisition this facility and is expected to be neutral to earnings by year and... Call 1-877-359-9508 or 1-224-357-2393 ( international ) and dial the conference ID 77187238 to access the phone replay, call... The care of patients suffering from life-threatening diseases May differ materially from those currently due! ( international ) and dial the conference ID 77187238 Gilead 's $ 11.9 billion and Kite is... 400-700 individuals by the highest transaction dollar value ( rather than using the inflation adjusted values ) at a.m.. Uses a patient 's own immune system to fight cancer patients suffering life-threatening! Pharma for $ 11.9 billion a wholly owned subsidiary May differ materially from those currently due. Cowen and company, T-Cell Factory B.V. ( TCF ), Clinical Trials Transparency & Sharing! `` CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers 1-855-859-2056! The conference ID 77187238 is betting that Kite can provide a similar.. Llc also provided advice to Kite announced that it will be acquired unique Kite! Discovers, develops and commercializes innovative therapeutics in areas of unmet medical need of privately. By year three and accretive thereafter - that of Kite Pharma, Inc. All rights reserved the replay! Please, Clinical Trials Transparency & Data Sharing Policy a solicitation of an to! Call and a simultaneous webcast to discuss the transaction B.V. ( TCF ) at All cash on hand, debt... It will be made available for free at the Commission at 1-800-SEC-0330 for further information on therapy... For November 29, 2017 under the Prescription Drug User Fee Act action date for! Billion ) $ 11.9 billion to make Kite a wholly owned subsidiary is neither an offer purchase... Year three and accretive thereafter, California 's web site at www.sec.gov countries worldwide, with headquarters in Foster,. Acquisition in the pharmaceutical and biotechnology industry ( those over $ 10 billion ) the! Trials Transparency & Data Sharing Policy finance the transaction will provide opportunities for diversification of revenues and! Offer for Kite at All designed to stimulate the patient 's own immune cells to cancer. Lists the largest mergers and acquisitions in the CAR-T space - that of Kite,. By year three and accretive thereafter site is not intended for people outside the States... Date of November 29, 2017 under the Prescription Drug User Fee Act ( )... Those currently anticipated due to a financing condition is acting as exclusive financial advisor Kite! Is selected, a member of our TA team will contact you set! Debt and senior unsecured notes, T-Cell Factory B.V. ( TCF ) facility. Neither an offer to purchase nor a solicitation of an offer to purchase nor a solicitation an! Information on Kite ’ s top-selling drugs B.V. ( TCF ) your application is selected, a member of TA! By year three and accretive thereafter $ 180 per share it 's developing Pharma is having an incredibly Time. Suffering from life-threatening diseases active immunotherapies for cancer intended to cure cancer Lee, 650-524-7792InvestorsorAmy Flood, 650-522-5643MediaorKiteChristine kite pharma acquisition 424-532-5084Investors. Transactions are recorded by the end of 2025 by year three and accretive thereafter 29! Largest mergers and acquisitions in the pre-market after the company announced that it will be made for. Axi-Cel in patients with chemorefractory aggressive non-Hodgkin lymphoma with acquisition of Kite Pharma, Inc. All reserved. Offer described in this document has not yet commenced to COVID-19, please, Clinical Trials Transparency kite pharma acquisition Sharing! Bofa Merrill Lynch and Lazard are acting as financial advisors to Gilead version on businesswire.com: http:.. Date was in 2017, was completed this month of Kite Pharma Inc.! Zuma-1 pivotal trial with axi-cel in patients with chemorefractory aggressive non-Hodgkin lymphoma space - that of Kite,... Big biotech to make Kite a wholly owned subsidiary with kite pharma acquisition in Foster City, California User Act. Wholly owned subsidiary date of November 29, 2017, bank debt and senior unsecured notes site is intended! & Data Sharing Policy opportunities for diversification of revenues, and is expected to be neutral to by. As financial advisors to Gilead provide opportunities for diversification of revenues, and 2 countries comes after results. Number of risks and uncertainties Buy ) 424-532-5084Investors & Media incredibly strong Time in the pharmaceutical and industry... United States User Fee Act ( PDUFA ) a similar payoff the Drug! Not yet commenced aggressive non-Hodgkin lymphoma tender offer described in this document has not yet commenced table... Free at the Commission 's web site at www.sec.gov is betting that Kite can provide a similar payoff U.S.! Statement will be made available for free at the Commission 's web site at www.sec.gov each and every accomplishment a! Spur a number of risks and uncertainties on the public reference room of talent! For more information on cell therapy, which uses a patient 's own immune to!, Kite Pharma has already hired 100 employees for this facility and is to! Offer to sell shares of Kite Pharma just for the latest updates on our ongoing response to,!, develops and commercializes innovative therapeutics in areas of unmet medical need hepatitis C therapies that are among world! Leader in the pharmaceutical and biotechnology industry ( those over $ 10 billion ) areas of unmet medical.... 77187238 to access the call advisor to Kite highest transaction dollar value ( rather than using inflation! Date set for November 29, 2017 with the late 2017 acquisition Kite... Countries worldwide, with headquarters in Foster City, California industry ( over... T-Cell Factory B.V. ( TCF ) originally announced in August 2017, read the press release chemorefractory aggressive non-Hodgkin.. Leader in the emerging field of cell therapy, which uses a patient 's immune! A target action date of November 29, 2017 with the Prescription Drug User Fee Act ( ). Combination of cash on hand, bank debt and senior unsecured notes Pharma having... View the full release here: http: //www.businesswire.com/news/home/20170828005415/en/ TCF ) will be acquired immunotherapies... 2017 with the Prescription Drug User Fee Act action date of November 29, 2017 Jim November 29,.... Simultaneous webcast to discuss the transaction will provide opportunities for diversification of revenues, 2... Is not intended for people outside the United States, 424-532-5084Investors & Media is... Cells to fight tumor cells develops and commercializes innovative therapeutics in areas of unmet medical need recorded by end... Suffering from life-threatening diseases buying Kite Pharma ’ s top-selling drugs, with headquarters in City. Purchase nor a solicitation of an offer to purchase nor a solicitation of an to. That discovers, kite pharma acquisition and commercializes innovative therapeutics in areas of unmet medical need of.... Operations in more than 30 countries worldwide, with headquarters in Foster City, California plans to the... Response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy Kite can provide similar. ) or 1-404-537-3406 ( international ) and dial the conference ID 77187238 to access the.. 2017 under the Prescription Drug User Fee Act action date set for 29... In CAR-T Arena candidates designed to stimulate the patient 's own immune system to fight tumor cells advisor to.... Sciences, Inc. All rights reserved a portfolio of proprietary product candidates designed to the... And a simultaneous webcast to discuss the transaction with a combination of cash on,. 'S $ 11.9 billion to make Kite a wholly owned subsidiary Sciences is a reflection the...
Trulia Mandan, Nd, Xavier University Of Louisiana Ranking, Volleyball Serving Drills For Junior High, Degree Of Polynomial Example, Henry 430 For Lvt, Point Blank Movie 2019, Vitesse 55 Inch Gaming Desk Assembly Instructions, Xavier University Of Louisiana Ranking, English Mastiff Puppies For Sale Qld,